We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Par Pharmaceutical will be able to launch a version of Unimed Pharmaceuticals' testosterone-replacement product AndroGel more than four years before patent expiration under terms of a settlement announced this week.